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Abstract
Backround: Micrometastases of colorectal liver metastases are present in up to 50% of lesions. In this study we sought 
to determine the threshold dose for local control of occult micrometastases in patients undergoing CT (computed 
tomography)-guided brachytherapy of colorectal liver metastases.
Materials and methods: Nineteen patients demonstrated 34 local tumor recurrences originating from 
micrometastases after CT-guided brachytherapy of 27 colorectal liver metastases. We considered a local tumor 
recurrence as originating from a micrometastasis if tumor regrowth occurred adjacent to a formerly irradiated lesion 
and the distance of the 3D isocenter of the new lesion was ≤ 23.5 mm from the previous tumor margin. Follow-up MRI 
was fused with the planning-CT and dosimetry data. Two reviewers independently indicated the dose exposure at the 
isocenter of the micrometastases. Statistical analysis included an analysis of variance (ANOVA) using backward 
selection. 95% tolerance intervals with coverage of 87.5 and 75% of the data of the normal distribution were calculated.
Results: The median distance of the micrometastases to the margin of the originating colorectal metastases was 8.75 
mm (1-21 mm). Dose exposure at the isocenter was 12.25 Gy (7-19.8) in median. We stratified according to the distance 
from the isocenter to the initial tumor margin: ≤ 9 mm, > 9-15 mm and > 15 mm. The median dose in the according 
isocenters was 13.18, 11.6 and 11.85 Gy. The threshold dose failing to prevent micrometastasis growth was sigificantly 
higher in a subgroup of lesions with ≤ 9 mm distance as compared to > 15 mm (13.18 vs 11.85 Gy). Adjuvant 
chemotherapy correlated with greater distance of micrometastasis growth to the tumor but not with the threshold 
dose.
Conclusion: To prevent loss of local tumor control by continuous growth of micrometastases a threshold dose of 15,4 
Gy (single fraction) should be delivered at a distance of 21 mm to the gross tumor margin.
Backround
For the treatment of liver metastases from colorectal car-
cinoma, surgery as well as percutaneous image guided
tumor ablation have demonstrated favourable results
with respect to an improvement of the patient's prognosis
[1-7]. Both the surgical as well as the minimal, or, in case
of percutaneous irradiation, non-invasive approach
require a safety margin around the target to reduce the
risk of a recurrence and to gain a better prognosis [1,8-
12]. Recent publications have drawn attention to the
presence of radiologically invisible micrometastases or
microsatellites, respectively (in the following we apply the
term micrometastases). These micrometastases directly
originate from and are found frequently adjacent to col-
orectal liver metastases [12-16].
Occult tumor cell nests such as micrometastases play a
significant role in recurrent tumor growth after local
tumor treatments. A histopathologic study of 31 liver
specimen after liver resection of colorectal metastases
demonstrated micrometastases deriving from neighbour-
ing macrometastases in 56% of the cases. The mean dis-
tance between micrometastasis and originating
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macrometastases was 7.5 mm (SD (standard deviation) 8
mm) [13]. Hence, treatment planning in liver metastases
irradiation must not only consider the radiologically visi-
ble tumor bulk, but also the extension of subclinical dis-
ease around the gross tumor. Radiobiologically, local
control of low cell densities is required. The according
dose will be lower than control doses for gross tumor vol-
umes [17,18]. Considering the distance subclinical micro-
metastases may have from the gross tumor volume,
knowledge about the control dose for micrometastases
helps to reduce the clinical target volume specifically in
irradiation techniques with steep dose gradients.
In the study described herein we retrospectively ana-
lyzed recurrent tumor growth after CT-guided
brachytherapy of colorectal liver metastases. We included
only patients displaying tumor recurrences identified as
originating from micrometastases around the initial tar-
get lesion. The aim of this study was to determine the
threshold dose for local control of micrometastases of
colorectal liver metastases.
Materials and methods
Patient identification
We included 19 patients (female, npatients = 8; male, npatients
= 11) with a mean age of 64 years (range 49-86 years). All
patients displayed nodular tumor regrowth (nlesions = 34)
during follow up after CT-guided brachytherapy of 27
colorectal liver metastases. These tumor recurrences
were classified as originating from micrometastases (for
definition of micrometastases see standard of reference).
Primary tumor site was colon in 11 and rectum in 8
patients. After CT-guided brachytherapy, 4 patients had
received chemotherapy (FOLFIRI (×1), irinotecan (×2),
FU/FA (×1)) as adjuvant treatment. All other patients did
not receive systemic treatment in the time interval
between local treatment and confirmation of tumor
regrowth.
Standard of reference and definitions
Colorectal liver metastases were confirmed by histopa-
thology prior to the initial CT guided brachytherapy.
Tumor burden prior to therapy was assessed by MRI
(magnetic resonance imaging) based volumetry. Diagno-
sis of local tumor recurrence during follow up was con-
firmed by tumor growth in contrast enhanced MRI. No
biopsy was taken from these tumor recurrences. We con-
sidered a local tumor recurrence to be originating from a
micrometastasis if all of the following applied:
a) the new lesion occurred adjacent to a previously
treated lesion.
b) the new lesion had a nodular shape applying a
asymmetrical appearance in conjunction with the
original, pretreated lesion.
c) The 3D isocenter of the new lesion was ≤ 23.5 mm
from the initial margin of the metastasis before
brachytherapy (adapted from histopathological stud-
ies by Nanko et al [13]) (figure 1).
Eligibility criteria
We excluded patients presenting a symmetric tumor
regrowth of the irradiated metastasis or patients with dis-
seminated new intrahepatic tumor deposits.
Interventional technique CT-guided brachytherapy
The technique of CT-guided brachytherapy has been
described elsewhere [19]. The placement of the
brachytherapy applicators was performed at a Fluoros-
copy CT (Siemens, Erlangen, Germany). For treatment
planning purposes, a spiral CT of the liver (slice thick-
ness: 5 mm; increment: 5 mm) enhanced by intravenous
administration of iodide contrast media (100 ml Ultravist
370, flow: 3 ml/s; start delay: 80 s) was acquired using
breathhold technique after positioning of the brachyther-
apy catheters in the tumor.
Depending on tumor geometry and lesion size, a
median of 4 catheters was used in our patients (range: 2 -
20 catheters).
The 3D CT data set acquired after catheter positioning
was transferred to the treatment planning unit (BrachyVi-
sion®, Varian Medical Systems, Charlottesville, VA, USA).
A Radiooncologist defined the CTV (clinical target vol-
ume) including a safety margin of 2 mm in the 3D CT
data. Threshold doses for local control of colorectal liver
Figure 1 Scheme of a follow-up MRI merged with the initial do-
simetry displaying a tumor recurrence of a micrometastasis (LR). 
The black cross in LR marks the 3D isocenter. The dashed line describes 
the CTV around the colorectal liver metastasis which had been treated 
initially. The bold dashed line outlines 23.5 mm distance from the initial 
tumor margin.Seidensticker et al. Radiation Oncology 2010, 5:24
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metastases using this approach have been published
recently [5]. No image fusion of MRI pre treatment with
planning CT was performed since in all patients tumor
conspicuity on CT was sufficient for treatment planning.
The prescribed and applied minimal dose inside the CTV
was 15 Gy at median (12 to 25 Gy).
The high dose rate afterloading system employed a
192Iridium source of 10 Ci (Gammamed®, Varian Medical
Systems, Charlottesville, VA, USA). The source diameter
was < 1 mm. Dwell positions were located every 5 mm.
Dwell times were corrected automatically according to
the actual source strength. The true mean duration of the
irradiation was 2018 seconds (range: 1088 to 4666 sec-
onds). Normalized to 10 Ci according to the actual source
strength the theoretical duration would have been 1633
seconds (range: 639 to 3825 seconds). A single dose rate
can not be calculated due to variable catheter geometries
and differing distances of tumor tissue to the catheters.
According to the irradiation time and the known minimal
dose at the tumor margin a minimal dose rate can be cal-
culated ranging from 11-84 Gy/h (mean 43).
MRI Baseline and Follow-up
All patients underwent MRI (Gyroscan NT 1.5T, Philips,
Best, The Netherlands) of the liver 1 day prior to
brachytherapy and in follow up 6 weeks and every 3
months after treatment. The MRI protocol consisted of
the following sequences: T2-w UTSE (T2-weighted ultra-
fast spinecho) (TE/TR (time to echo/timo to repetition)
90/2100 ms) with and without fat suppression, T1-w GRE
(T1-weighted gradient recalled echo) (TE/TR 5/30 ms,
flip angle 30°) pre-contrast, 20 s post intravenous admin-
istration of 15 ml Gd-BOPTA (Gadobenate dimeglumine,
Multihance®, Bracco, Princeton, USA), and 2 h post injec-
tion of intravenous Gd-BOPTA. The slice thickness was 5
mm (T1-w sequences) and 8 mm (T2-w sequences)
acquired in interleaved mode with no gap applied.
Tumor assessment and image registration
Plain T1-w GRE sequences were used to determine the
location and the size of nodular local tumor recurrences
[20]. Image fusion of the MRI sequence showing the
regrowth of the micrometastases with the former treat-
ment plan was performed by BrachyVision®. The algo-
rithm employs a rigid local semi-automated point based
3D-3D image registration. Match points were defined on
corresponding landmarks such as branches of the portal
vein to enable fusion of MR and planning CT/dosimetry
data. Landmarks were restricted to the liver and chosen
as close to the lesion as possible, i.e. limited to the identi-
cal liver lobe. As a result of this procedure, BrachyVision®
simultaneously displayed the treatment plan as well as
the anatomical structures of the MRI with a maximum
deviation of < 5 mm (figure 2).
One radiologist and one radiooncologist (reader 1 and
2) evaluated the combined MRI/dosimetry data indepen-
dently. The reviewers individually calculated the largest
diameter of the recurrent tumor mass, its 3D-isocenter
coordinates ("center of the recurrent mass") as well as the
dose at this respective point. In addition, they measured
the distance of the 3D isocenter to the initial tumor mar-
gin prior to the first brachytherapy. By image fusion of
MRI (T1-w GRE pre contrast) 1 day prior to treatment
with follow up MRI visible tumor as origin of the recur-
rent tumor mass could be excluded.
Statistical analysis
Results of continuous data are displayed as medians and
ranges, results of frequency data as counts and percent-
ages. For the analysis, independence between lesions
within the same patient was assumed as the treatment
was applied locally and not systemic, so that the treat-
ment of one lesion did not affect a second lesion and any
micrometastasis with this second lesion.
The agreement between the two readers evaluating the
applied dose was measured by the intra-class correlation
coefficient based on a linear model.
For two-group comparisons of the medians two-sided
Wilcoxon rank sum tests were used. Measured doses
were assumed to be normally distributed. Therefore t-
Tests were used to test for pairwise differences in doses.
We used a mixed linear model to account for the repeated
measurements of doses for each lesion by the two read-
ers. Independence was used as working correlation
matrix.
Important independent factors to explain the variation
of the measured dose in the center of the recurrent mass
were evaluated by an analysis of variance (ANOVA) using
backward selection to select significant factors. Based on
the final model, 97.5% upper tolerance limits with cover-
age of 87.5% and 75% were calculated. The maximum
upper tolerance limit (incuding 87.5% or 75% of the data,
respectively) for all combinations of significant factors
were used to define the "insufficient doses to prevent
micrometastasis growth". The tolerance intervals were
extrapolated to a maximum distance of 23 mm from the
limit of the primary lesion as the data only contained data
up to 21 mm. p-values below 0.05 were regarded as statis-
tically significant.
Calculations were performed using R software (version
2.7.1, R Development Core Team (2008)) and SAS® 9.2
(SAS-Institute, Cary, NY).
Results
The mean diameter of the colorectal metastases treated
by CT-guided brachytherapy was 4.5 cm (range 1.5-11
cm), the volume 50 ccm (range 3-630 ccm). The shape of
the respective metastases was oligonodular (asymmetricSeidensticker et al. Radiation Oncology 2010, 5:24
http://www.ro-journal.com/content/5/1/24
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Figure 2 A: planning CT with overlayed dosimetry (BrachyVision®) showing a colorectal liver metastasis in segment 8. One catheter tip is dis-
played directly (black arrow), more catheters in other levels of the liver are indicated by green arrows. Verification of correct definition of the CTV was 
performed by image fusion of the planning CT with a MR scan (T1 GRE without contrast media) obtained 3 days prior to treatment (B). Local recurrence 
(white arrow) 6 months after treatment (MR, T1 GRE without contrast media, C). The distance of the 3D isocenter of the local recurrence from the initial 
tumor margin is 9 mm. Thus, the local tumor recurrence meets the criteria for micrometastasis growth (D). The dose initially applied in the center of 
the micrometastasis was 10.9 Gy.Seidensticker et al. Radiation Oncology 2010, 5:24
http://www.ro-journal.com/content/5/1/24
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confluent) versus round (regular spheroid) in 32% and
68% of lesions, respectively. The minimal dose at the
tumor margin applied during CT-guided brachytherapy
was 15 Gy (range 12-25 Gy). The activity factor of the
192Iridium source was 1.17 (range 0.97-1.83).
Recurrent tumor categorized as micrometastasis
growth was depicted at a mean follow up of 6 months
(range 3-22 months) with 88% of all lesions occuring
within 12 months.
Local tumor recurrences from micrometastases dis-
played a mean axial diameter of 1.5 cm (range 0.8-2.4
cm), the mean tumor volume was 1.76 ccm (0.27-7.23
ccm).
The distance of the 3D isocenter of the micrometasta-
ses to the margin of the originating colorectal metastases
was 8.75 mm (range 1-21 mm, Q25: 3 mm, Q75: 15 mm).
The dose in the 3D-isocenter of the micrometastases
was 12.95 Gy (Reader 1: 7.33-18.75 Gy, Q25: 10.93 Gy,
Q75: 13.47 Gy) and 12.25 Gy (Reader 2: 7-19.8 Gy, Q25:
10.5 Gy, Q75: 13.5 Gy) (figure 3).
The interobserver-correlation was 0.86 (figure 4). Since
the interobserver-correlation yielded this very high
agreement, a cumulative evaluation was performed dur-
ing further analyses.
We stratified tumor recurrences from micrometastases
according to the distance from the 3D-isocenter to the
initial tumor margin: ≤ 9 mm (n = 18), > 9-15 mm (n = 8)
and > 15 mm (n = 8). The median dose across readers in
the according isocenters was 13.18 Gy, 11.6 Gy and 11.85
Gy, respectively (figure 5). Significant pairwise differ-
ences between the groups were only found for distances ≤
9 mm as compared to > 15 mm for the assessments across
readers (p = 0.0442).
Stratification of the tumor recurrence from microme-
tastases according to a history of adjuvant chemotherapy
(yes/no) after initial irradiation showed a significantly
higher distance of the 3D-isocenter to the originating
metastases when adjuvant chemotherapy was applied (p
= 0.0038) (figure 6). However, despite the influence of
adjuvant chemotherapy regarding the distance of the iso-
center, lower dose levels at greater distances as a result of
the dose gradient failed to reach significance (p > 0.05).
Results of the ANOVA analysis are displayed in table 1.
Upper 97.5% tolerance limits were calculated with cover-
age of 87.5% and 75% of the data. In essence, doses indi-
cated refer to the threshold doses avoiding tumor growth
from micrometastases in 87.5% or 75% of the cases. The
Maximum upper 97.5% tolerance limit with coverage of
87.5% for the distance of 21 was 15.4 Gy: 87.5% of the
doses in the isocenters of the micrometastases with a dis-
Figure 3 Boxplot of the point dose at the center of each microme-
tastasis as indicated by both readers.
Figure 4 Intra-class correlation for comparison of the readers 
demonstrating a very high interobserver correlation (0.86).
Figure 5 Boxplot of the dose at the 3D isocenter of each micro-
metastasis grouped according to the distance to the margin of 
the originating metastases across readers. The difference between 
the doses measured in the group ≤ 9 mm (in median 13.18 Gy) and > 
15 mm (in median 11.85 Gy) was significant (p = 0.0442).Seidensticker et al. Radiation Oncology 2010, 5:24
http://www.ro-journal.com/content/5/1/24
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tance of < 21 mm to the initial tumor margin were less
than 15.4 Gy. Thus < 15.4 Gy at a distance of < 21 mm
was insufficient to avoid tumor growth from micrometas-
tases in 87.5% of the cases.
As independent factors the distance between the isoce-
nter and the initial tumor margin (the higher the distance
the lower the dose, p = 0.0004) as well as the geometry of
the initial liver lesion (oligonodular shape was associated
with a higher threshold dose, p = 0.009) significantly
influenced the threshold doses for micrometastasis
growth. The size of the irradiated colorectal liver metas-
tases showed no influence on the threshold dose.
Discussion
In surgical and local treatment of colorectal liver metas-
tases the margin status is consistently related to progno-
sis after treatment. Numerous authors have investigated
the significance of margin status for resection of colorec-
tal liver metastases [1,8-12]. Although the existence of
positive margins is shown to account for a high rate of
local recurrences, practical guidelines for the extent of a
safety margin are not fully understood. Surgical studies
dedicated to this issue have demonstrated a lower rate of
local tumor recurrences in patients resected with a safety
margin > 1 cm margin [9,12]. In a study of Wray et al. in
112 patients undergoing liver resection with a safety mar-
gin < 1 cm 45% developed a local tumor recurrence [9].
These clinical observations are supported by histo-
pathological findings. Previous authors have described a
d i r ec t  i n va s i o n  o f  ca n c e r  c e l l s  i n t o  b i l e  d u c t  a n d  l ym -
phatic vessels inducing satellite lesions in close distance
[12,13]. The frequency of such lesions termed microme-
tastases or microsatellites is influenced by distance to the
macrometastases, presence of a pseudocapsule, lympho-
cyte infiltration separating metastases and neighbouring
liver parenchyma, and the morphologic type of the lesion
(round vs. oligonodular) [13,14,21,22]. Histopathologi-
cally, micrometastases were depicted more often with the
confluent nodular (oligonodular) morphology [22]. A
recent study has proven a negative impact of oligonodular
lesion shape on local progression free survival in colorec-
tal cancer patients undergoing irradiation therapy (CT-
guided brachytherapy) of liver metastases [5]. These find-
ings suggest that the presence of micrometastases fre-
quently found in oliginodular lesions may at least in part
be responsible for early local failures.
Hence, the presence of radiologically occult microme-
tastases around colorectal liver metastases has to be con-
sidered when delineating the clinical target volume for
local irradiation. Nanko et al. [13] described the mean
distance of micrometastases to the margin of the radio-
logically visible macrometastases of 7.5 mm ± 8 mm. An
explanation for this high standard deviation was not
stated by the authors; however, a low number of micro-
metatastases at a larger distance to the initial tumor mar-
gin might have been causative. Assuming an underlying
Gaussian distribution 95% of the micrometastases were
found in a distance of < 23,5 mm. This calculation led to
our definition of micrometastasis regrowth, with asym-
metrical, nodular growth at a total distance of ≤ 23.5 mm
from the initial tumor margin after brachytherapy. In our
study, the mean distance from the 3D isocenter of the
micrometastases to the former tumor border was 9.6 mm
± 6.5 mm (median: 8,75 mm). This finding correlates
closely with the histopathological data published by
Nanko et al. of 7.5 mm ± 8 mm and it supports the valid-
ity of our definition of micrometastases [13].
Furthermore, both histopathology by Nanko et al. as
well as our own data describe a higher rate of microme-
tastases in close proximity to the tumor margin (74 and
53% ≤ 9 mm, respectively) [13]. In addition, the cell den-
sity in these nearby lesions has been described to be
higher than at greater distance [13,16]. Wakai et al
described a tenfold higher cell densitiy of the microme-
tastases in the close zone of ≤ 10 mm around the tumor
compared to the distant zone > 10 mm [16]. Radiobiolog-
ically, a higher radiation dose is needed to achieve com-
plete cell kill in areas of higher tumor cell density [17,18].
Figure 6 Distance of the micrometastases to the former tumor 
margin stratified by history of adjuvant chemotherapy (yes: fig-
ure 6 A, no: figure 6 B), whereas tumor growth occurred in signif-
icantly greater distance from the originating metastasis when 
adjuvant chemotherapy was applied (p = 0.0038)— related lower 
dose levels failed to reach statistical significance (p > 0.05).Seidensticker et al. Radiation Oncology 2010, 5:24
http://www.ro-journal.com/content/5/1/24
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Table 1: Results of the ANOVA analysis
Distance of the local recurrence to the 
former tumor margin
(mm)
Maximum upper 97.5% tolerance limit 
with coverage of 87.5%
(Gy)
Maximum upper 97.5% tolerance limit 
with coverage of 75%
(Gy)
1 18.66 17.56
2 18.49 17.40
3 18.32 17.23
4 18.16 17.06
5 17.99 16.90
6 17.82 16.73
7 17.66 16.57
8 17.49 16.41
9 17.33 16.24
10 17.17 16.08
11 17.01 15.92
12 16.85 15.76
13 16.69 15.59
14 16.53 15.43
15 16.37 15.27
16 16.22 15.11
17 16.06 14.96
18 15.90 14.80
19 15.75 14.64
20 15.60 14.48
21 15.45 14.33
22 15.30 14.17
23 15.15 14.01
Maximum upper 97.5% tolerance limits with coverage of 87.5% and 75%. 87.5% means that 87.5% of the data (dose measured in the center 
of the micrometastasis) are below the upper limit of the tolerance interval (with a confidence of 97.5%).
The Maximum upper 97.5% tolerance limit with coverage of 87.5% for the distance of 21 mm was 15.4 Gy: 87.5% of the doses in the isocenters 
of the micrometastases with a distance of < 21 mm to the initial tumor margin were less than 15.4 Gy. Thus < 15.4 Gy at a distance of < 21 
mm was insufficient to avoid tumor growth from micrometastases in 87.5% of the cases.Seidensticker et al. Radiation Oncology 2010, 5:24
http://www.ro-journal.com/content/5/1/24
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The histopathological proof of higher cell density of
micrometastases at close proximity may well explain our
own finding that micrometastases located nearby the
macrometastases occurred despite marginally increased
doses (table 1 and figure 5).
The inherent advantage of computed tomographic
guidance for interstitial irradiation of liver malignancies
is the accuracy of the dose administration whereas exter-
nal beam liver radiotherapy is hampered by a discrepancy
between planned and radiated target, mainly due to
breathing movements of the organ (up to 10 mm in cran-
iocaudal direction) [23,24]. Therefore, the PTV in exter-
nal beam liver radiotherapy exceeds the CTV
substantially [3]. In CT-guided brachytherapy the cathe-
ters are positioned and fixed inside the tumor. Hence,
organ motion is not a limiting factor and the CTV and
PTV are theoretically not different. An implementation
of the gained data regarding the threshold dose of micro-
metastases in treatment planning of CT guided
brachytherapy of colorectal liver metastases seems feasi-
ble whereas in external beam liver radiotherapy an addi-
tional extension of the radiated field will cumber at least
the therapy of big metastases.
With respect to the methodology used, some aspects
need to be discussed. First, although performing a locally
focused 3D-3D registration of the liver CT and MRI the
deviation was up to 5 mm. This mismatch in image regis-
tration of CT and MRI of the liver is in good congruence
to other studies [25,26]. Due to different modalities and
possible organ distortion between the image studies a
small registration error is not avoidable. The direction of
registration mismatch is variable and not systemetical,
thus we do believe that the margin as calculated by us
accounts for this deviation.
Second, our determination of the 3D isocenter of a
micrometastasis as its primary location was based on the
assumption of centrifugal tumor growth [27-30]. Simu-
lated three-dimensional tumor growth dynamics of brain
tumors by Kansal et al. revealed spherical growth even if
multiple cell strains participated in growth [31].
Third, statistical analysis by ANOVA was used to deter-
mine the threshold doses failing to prevent micrometas-
tasis growth after brachytherapy. In consequence, our
assumptions are limited to the negative proof in lesions
displaying treatment failure. The positive affirmation, i.e.
the dose assuring micrometastasis control could not be
tested since micrometastases were occult at the time of
the initial treatment. However, the consistency of the data
drawn from the negative proof in this study is extremely
high. As can be seen in table 1, an increasing distance of
the isocenter of the micrometastases from the originating
metastases corresponds to a quite discrete linear dose
decline for both the 87.5% and the 75% interval. Stratifi-
cation in micrometastases at a distance of < 9 mm, 9-15
mm and > 15 mm revealed significance for the threshold
dose only for nearby lesions compared to the very dis-
tanced lesions, a phenomenon which we attribute to the
decreasing cell density of remote micrometastases as has
been proven by histopathology [13,16]. In contrast to
this, in CT-guided brachytherapy the dose gradient out-
side the CTV typically shows a strong decline to approxi-
mately 25% of the dose at a distance of 2 cm [32]. We
conclude that our results gained by employing the nega-
tive proof are statistically very consistent and thus dem-
onstrated their validity for the determination of the
threshold dose to prevent recurrent micrometastasis
growth.
In summary, micrometastases are frequent in patients
with colorectal liver metastases. According to histo-
pathological results, micrometastases may be encoun-
tered in up to 50% of metastases with a predominance in
lesions displaying an oligonodular shape. To prevent loss
of local tumor control by continuous growth of microme-
tastases after single fractioned irradiation of colorectal
liver metastases, we recommend to deliver a dose of at
least 15,4 Gy at a distance of 21 mm to the gross tumor
margin. Adjuvant chemotherapy had a positive impact on
the development of tumor growth from micrometastases.
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